SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Corsee D. Sanders, Ph.D., as Executive Vice President and Head of Development Operations, effective immediately. She will be responsible for the planning, management, execution, analysis, and reporting of Juno’s clinical trials. Prior to joining Juno, Dr. Sanders was Senior Vice President and Head of Global Clinical Operations and Industry Collaborations at Roche Pharmaceuticals.
“Corsee is a dynamic leader, and a terrific addition to our executive team,” said Hans Bishop, President and CEO of Juno. “Juno’s next phase of growth will benefit from her expertise in the data sciences, her experience leading complex development organizations, and her relentless focus on execution as a strategic advantage.”
Prior to her tenure at Roche, which included three years as Head of Global Biometrics and Development Innovation, Dr. Sanders worked in a number of senior leadership roles at Genentech, Inc., where her responsibilities included biostatistics, epidemiology, health economics and outcomes research, data management, medical writing, information technology, and biosample management.
Dr. Sanders will report to Mr. Bishop and will be a member of the firm’s Executive Committee. She will lead a newly organized Development Operations group that will combine clinical operations, biometrics and data management, patient operations, medical writing, and program and project management.
“I am delighted to join Juno at an exciting time in the company’s history, and am looking forward to being a part of developing innovative new medicines for patients with difficult diseases,” said Dr. Sanders. “I have been privileged to be a part of bringing highly successful products to market at other companies and am excited to bring that experience to Seattle and Juno.”
In her 23 years with Genentech and Roche, Dr. Sanders oversaw diverse aspects of early-to-late development programs spanning the therapeutic areas of oncology, immunology, pulmonary, rheumatology, respiratory, neurology, ophthalmology, cardiovascular, inflammatory bowel disease, endocrinology, and infectious disease. She was instrumental in the development and submission of Rituxan, Herceptin and its companion diagnostic Herceptest, and Avastin. She also led the planning and execution for the development of other products at both companies.
Dr. Sanders holds bachelor’s and master’s degrees in statistics from the University of the Philippines, and received a master’s degree and doctorate in statistics from the Wharton School at the University of Pennsylvania.
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, organizational plans, and business plans. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2016 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.